Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

NCT ID: NCT05812027 Phase: N/A Sponsor: TScan Therapeutics, Inc. Status: Active Not Recruiting

SUMMARY

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.

KEY ELIGIBILITY CRITERIA

- * Willing and able to provide written informed consent.
- * Male or female aged e18 years at the time of signing the informed consent.
- * Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor for which the Sponsor has an associated clinical study:
- * Head and neck cancer
- * Cervical cancer
- * Non-small cell lung cancer
- * HPV positive anogenital cancers
- * Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate.
- * Willing to provide a buccal swab for HLA testing
- * Willing to provide a saliva sample to use as a normal control for the LOH assay

Total sites: 21 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT05812027) and public sources. Generated by FindMyCure.ai.